Inventiva S.A. (IVA) Stock Score, Valuation & Financial Research
Inventiva S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for IVA
Inventiva S.A. currently has a Wall Street Score of 25/100. The stored market price is $3.86. Its financial score is 8/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Inventiva S.A. does
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with
IVA financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $3.86
- Market capitalization:
- $200.7M
- Revenue:
- $15.9M
- Net income:
- $-623.1M
- Free cash flow:
- $-117.4M
- Cash:
- $115.2M
- Total debt:
- $68.9M
- EPS:
- -5.44
- Financial score:
- 8/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +2.1%.
- Free cash flow is $-117.4M, showing cash burn in the current stored period.
- The balance sheet shows $115.2M of cash versus $68.9M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.3 points: IVA increased 0.3 points because Asset improved by 3 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research IVA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.